Thus, over the past three decades research on peptide-based radiopharmaceuticals targeting the cholecystokinin-2 receptor (CCK-2R), which is overexpressed in over 90% of all MTC patients [4], has been progressing. The gene discussed is CCKBR; the disease is medullary thyroid gland carcinoma.